ALT
Price:
$6.2
Market Cap:
$440.64M
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryla...[Read more]
Industry
Biotechnology
IPO Date
2017-05-26
Stock Exchange
NASDAQ
Ticker
ALT
According to Altimmune, Inc.’s latest financial reports and current stock price. The company's current ROE is -60.51%. This represents a change of 301.34% compared to the average of -15.08% of the last 4 quarters.
The mean historical ROE of Altimmune, Inc. over the last ten years is 53.82%. The current -60.51% ROE has changed -212.42% with respect to the historical average. Over the past ten years (40 quarters), ALT's ROE was at its highest in in the December 2016 quarter at 399.82%. The ROE was at its lowest in in the September 2017 quarter at -61.24%.
Average
53.82%
Median
-45.64%
Minimum
-95.37%
Maximum
996.21%
Discovering the peaks and valleys of Altimmune, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 122.42%
Maximum Annual ROE = 996.21%
Minimum Annual Increase = -4920.55%
Minimum Annual ROE = -95.37%
Year | ROE | Change |
---|---|---|
2023 | -45.57% | -0.33% |
2022 | -45.72% | -5.33% |
2021 | -48.29% | 122.42% |
2020 | -21.71% | -51.83% |
2019 | -45.08% | -44.40% |
2018 | -81.08% | -14.99% |
2017 | -95.37% | -109.57% |
2016 | 996.21% | -4920.55% |
2015 | -20.67% | -62.07% |
2014 | -54.48% | -65.90% |
The current ROE of Altimmune, Inc. (ALT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-46.53%
5-year avg
-41.27%
10-year avg
53.82%
Altimmune, Inc.’s ROE is less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Athira Pharma, Inc. (-95.53%), greater than Fortress Biotech, Inc. (-226.63%), less than ACADIA Pharmaceuticals Inc. (6.89%), greater than Cabaletta Bio, Inc. (-43.98%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Inozyme Pharma, Inc. (-68.93%), greater than Viking Therapeutics, Inc. (-15.05%), greater than Anavex Life Sciences Corp. (-30.62%), greater than Cassava Sciences, Inc. (-10.98%), greater than INmune Bio, Inc. (-101.34%), greater than BioVie Inc. (-294.42%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than Ardelyx, Inc. (-39.73%), greater than Zura Bio Limited (-35.45%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than AVROBIO, Inc. (29.68%), greater than Verastem, Inc. (-133.02%), less than X4 Pharmaceuticals, Inc. (32.93%), less than Galera Therapeutics, Inc. (21.95%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than HOOKIPA Pharma Inc. (-51.77%),
Company | ROE | Market cap |
---|---|---|
7.96% | $44.68M | |
-95.53% | $20.81M | |
-226.63% | $40.38M | |
6.89% | $2.67B | |
-43.98% | $208.10M | |
-29.56% | $1.83B | |
-39.58% | $549.60M | |
-95.61% | $5.30B | |
-68.93% | $312.42M | |
-15.05% | $6.00B | |
-30.62% | $436.70M | |
-10.98% | $1.29B | |
-101.34% | $116.32M | |
-294.42% | $15.23M | |
-118.11% | $22.87M | |
-39.73% | $1.32B | |
-35.45% | $230.86M | |
-328.66% | $4.20M | |
29.68% | $5.24M | |
-133.02% | $96.58M | |
32.93% | $109.78M | |
21.95% | $4.08M | |
-122.70% | $1.25B | |
-51.77% | $159.50M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Altimmune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Altimmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Altimmune, Inc.'s ROE?
How is the ROE calculated for Altimmune, Inc. (ALT)?
What is the highest ROE for Altimmune, Inc. (ALT)?
What is the 3-year average ROE for Altimmune, Inc. (ALT)?
What is the 5-year average ROE for Altimmune, Inc. (ALT)?
How does the current ROE for Altimmune, Inc. (ALT) compare to its historical average?